Ceribell forecasts FY 2026 revenue of $114 million-$117 million
CBLL•FY 2026 revenue guidance and market opportunity
- Ceribell issued FY 2026 revenue guidance of $114 million-$117 million on Aug. 10, 2026.
- Q2 2026 revenue rose 33% year over year; YTD 2026 gross margin was 90% as of June 30, 2026.
- Management pegged the U.S.-only market opportunity at $3.5 billion, including an adult seizure acute care market of more than $2 billion.
- Pediatric and neonate indication expansion added an estimated $400 million opportunity; commercial launch began in Q1 2026.
